Target intelligence / Profile preview

Opioid receptors and other monoaminergic, muscarinic, and voltage-gated calcium channels

Molecular classification
G protein-coupled receptor, Ion channel, Transporter
01

Overview

The term Opioid receptors and other monoaminergic, muscarinic, and voltage-gated calcium channels refers to a diverse collection of physiological targets involved in pain modulation and autonomic signaling rather than a single protein. Opioid receptors (Mu, Delta, Kappa) are G protein-coupled receptors (GPCRs) that primarily mediate analgesia and reward, while monoaminergic targets (such as serotonin and norepinephrine transporters) regulate mood and descending inhibitory pain pathways. Muscarinic receptors and voltage-gated calcium channels further contribute to neurotransmitter release and excitability within the central and peripheral nervous systems. This broad grouping is often used to describe the complex polypharmacology of multi-target analgesics like methadone or nefopam, which achieve efficacy by simultaneously modulating several of these pathways. Because this entry combines multiple distinct protein families, it does not represent a single canonical therapeutic target.

Other names
Mixed opioid and non-opioid analgesic targetsMulti-target analgesic profile
02

Mechanism of action

This entry represents a heterogeneous group of pharmacological targets rather than a single molecular entity. Drugs interacting with this set typically act via G protein-coupled receptor modulation (opioid and muscarinic receptors), inhibition of monoamine reuptake (transporters), and blockade of ion conductance (calcium channels).

03

Biological functions

Signal transductionNeurotransmissionNociceptionMuscle contractionAutonomic regulation
04

Disease associations

Chronic painAcute painNeuropathic painOpioid use disorderDepression
05

Safety considerations

Respiratory depressionDependency and abuse potentialAnticholinergic toxicitySerotonin syndromeCardiovascular instability (QT prolongation)
06

Interacting drugs

Methadone

5 more in the full profile.

07

Biomarkers

Mu-opioid receptor expression levelsMonoamine metabolite levels (5-HIAA, HVA)Quantitative sensory testing (QST)

Beyond the preview

Go deeper on Opioid receptors and other monoaminergic, muscarinic, and voltage-gated calcium channels.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opioid receptors and other monoaminergic, muscarinic, and voltage-gated calcium channels.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call